Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement.

Ignacio EspañolMarta RomeraMaría Dolores Gutiérrez-MecaMaria Del Carmen GarcíaAurelia TejedorAntonio MartínezJerónima IbáñezFelipe De ArribaAlfredo MinguelaTeodoro IturbeMaria Dolores López

Published in: Clinical case reports (2017)

The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments.

Keyphrases

multiple myeloma
newly diagnosed
end stage renal disease
chronic kidney disease
ejection fraction
peritoneal dialysis
low dose
high dose
patient reported outcomes